GE-10 IDENTIFICATION OF PATIENTS WITH RECURRENT GBM THAT BENEFIT FROM BEVACIZUMAB

INTRODUCTION: To assess the effects of bevacizumab (BEV) in recurrent GBMs, a three-arm randomized phase II study was initiated (the BELOB trial) comparing BEV monotherapy, CCNU monotherapy and BEV + CCNU combinationtherapy. Primary endpoint was 9 months OS and was 38% [25,51], 43% [29,57] and 59% [...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Eraslan, Lale Erdem, van den Bent, Martin, Kros, Johan, Oosterkamp, Hendrika, Walenkamp, Annemiek, Beerepoot, Laurens, Hanse, Monique, Buter, J., Honkoop, Aafke, van der Holt, Bronno, Vernhout, R.M., Smitt, Peter Sillevis, Taal, Walter, French, Pim
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2014
Assuntos:
Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4218174/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou256.10
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados